NaDeNo Featured in Norwegian SciTechNews
What you’ll learn in this article
This article from Norwegian SciTech News will provide deeper understanding of NaDeNo’s innovative nanoparticle-based drug delivery system.
The company NaDeNo is developing a safer and more effective treatment for peritoneal cancer by encapsulating anti-cancer cytotoxins in nanoparticle carriers. The illustration shows a cancer cell and the nanoparticle carriers. Stock photo: Shutterstock
Peritoneal cancer is difficult to treat and has a poor survival prognosis. But a new and effective nanomedicine delivery system is offering some hope.
The company is called NaDeNo and is well underway with the development of a new cure for cancers that have spread to the peritoneal cavity. It is a spin-off from SINTEF, where the technology was developed over a period of more than ten years within nanomedicine research.
The work from which NaDeNo has evolved started in 2012. Initial research at SINTEF yielded promising results, and now both the technology and its patents are being spun off from the research institute and into a separate company.
The technology makes it possible to embed large volumes of an active cancer drug in nanoparticle carriers. These carriers are then injected into the peritoneal cavity, enabling the drug to be evenly distributed and thus delivered to all the tumours developed in the peritoneum.